for or infusion catheter administration it will be recognized that other methods for drug delivery or routes of administration may also be useful e g injection by the intravenous intralymphatic intrathecal intraarterial local delivery by implanted osmotic pumps or other intracavity routes administration of tgf beta activators or production stimulators in accordance with the present invention may be continuous or intermittent depending for example upon the recipient 39 s physiological condition whether the purpose of the administration is therapeutic or prophylactic and other factors known to skilled practitioners in the practice of certain embodiments of the present invention catheter and other administration routes are preferably conducted using a tgf beta activator or production stimulator dispersed in a pharmaceutically acceptable carrier that is in liquid phase useful pharmaceutically acceptable carriers include the generally employed carriers such as phosphate buffered saline solution water emulsions e g oil water and water oil emulsions and wetting agents of various types the invention will be better understood by making reference to the following specific example impact of tamoxifen on vascular smooth muscle cells and the relationship thereof to tgf beta production and activation cell culture dna synthesis assay and cell counting rat vascular smooth muscle cells were cultured after enzymatic dispersion.